Search Results (141)

A natural deep eutectic solvent (NADES)-based electropolymerization strategy was developed to deposit polypyrrole (PPy) and Naproxen-doped PPy films onto a biomedical Ti–20Zr–5Ta–2Ag high-entropy alloy. Using cyclic voltammetry, chronoamperometry, and chronopotentiometry, coatings were grown potentiostatically (1.2–1.6 V) or galvanostatically (0.5–1 mA) to fixed charge values (1.6–2.2 C). Surface morphology and composition were assessed by optical microscopy, SEM and FTIR, while wettability was quantified via static contact-angle measurements in simulated body fluid (SBF). Electrochemical performance in SBF was evaluated through open-circuit potential monitoring, potentiodynamic polarization, and electrochemical impedance spectroscopy. Drug-release kinetics were determined by UV–Vis spectrophotometry and analyzed using mathematical modelling. Compared to uncoated alloy, PPy and PPy–Naproxen coatings increased hydrophilicity (contact angles reduced from ~31° to <10°), and reduced corrosion current densities from 754 µA/cm² to below 5.5 µA/cm², with polarization resistances rising from 0.06 to up to 37.8 kΩ·cm². Naproxen incorporation further enhanced barrier integrity (R_coat up to 1.4 × 10¹¹ Ω·cm²) and enabled sustained drug release (>90% over 8 days), with diffusion exponents indicating Fickian (n ≈ 0.51) and anomalous (n ≈ 0.67) transport for potentiostatic and galvanostatic coatings, respectively. These multifunctional PPy–Naproxen films combine robust corrosion protection with controlled therapeutic delivery, supporting their potential biomimetic role as smart coatings for next-generation implantable devices. Full article

Phase change materials (PCMs) have significant potential for utilization due to their high energy storage density and excellent safety in energy storage. In this research, a flexible heat storage device using the stable supercooling of sodium acetate trihydrate composite is developed, enabling on-demand heat release through controlled solidification initiation. The solidification and heat release characteristics are investigated in experiments. The results indicate that the heat release characteristics of this heat storage device are closely linked to the crystallization process of the PCM. During the experiment, based on whether external intervention was needed for the solidification process, the PCM manifested two separate solidification modes—specifically, spontaneous self-solidification and triggered-solidification. Meanwhile, the heat release rates, temperature changes, and crystal morphologies were observed in the two solidification modes. Compared with spontaneous self-solidification, triggered-solidification achieved a higher peak surface temperature (53.6 °C vs. 46.2 °C) and reached 45 °C significantly faster (5 min vs. 15 min). Spontaneous self-solidification exhibited slower, uncontrollable heat release with dendritic crystals, while triggered-solidification provided rapid, controllable heat release with dense filamentous crystals. This controllable switching between modes offers key practical advantages, allowing the device to provide either rapid, high-power heat discharge or slower, sustained release as required by the application. According to the crystal solidification theory, the different supercooling degrees are the main reasons for the two solidification modes exhibiting different solidification characteristics. During solidification, the growth rate of SAT crystals exhibits substantial disparities across diverse experiments. In this research, the maximum axial growth rate is 2564 μm/s, and the maximum radial growth rate is 167 μm/s. Full article

Background: In burn injuries, wound healing effectiveness is complex and influenced significantly by the local biochemical environment and the physicochemical properties of topical preparations. pH lesions modulation can influence protection barrier integrity, inflammatory responses, and microbial colonization. Their antioxidant, antimicrobial, and anti-inflammatory properties, of the topical formulations enriched with plant extracts have demonstrated promising results. Objective: The aim of the study was to develop and characterize topical oleogel and hydrogel formulations containing ethanolic and hydroalcoholic extracts of medicinal plants (Boswellia serrata, Ocimum basilicum, Sambucus nigra, and Galium verum), and to evaluate the impact of their physicochemical properties, rheological behavior, in contrast with the wound pH modulation, and healing efficacy in an experimental burn model. Methods: Second-degree burns were induced uniformly on Wistar rats using the validated RAPID-3D device. All formulations were applied daily for 21 days, and wound healing was assessed through several measurements specific to the wound surface, skin temperature, pH, and, last but not least, histological analyses. Formulations’ physicochemical and rheological properties, including pH, viscosity, and spreadability, were also analyzed and systematically characterized. Results: Oleogel formulations demonstrated superior wound healing performance compared to hydrogels. Formulations containing Boswellia serrata and Ocimum basilicum extracts significantly reduced wound size, inflammation, and melanin production by days 9 and 21 (p < 0.05). The beneficial outcomes correlated strongly with formulation acidity (pH < 6), high viscosity, and enhanced thixotropic behavior, indicating improved adherence and sustained bioactive compound release. Histological evaluations confirmed enhanced epithelialization and reduced inflammation. Conclusions: Particularly Boswellia serrata and Ocimum basilicum in oleogel formulations in ethanolic solvent effectively modulated wound pH, enhanced topical adherence, and improved burn wound healing. These findings highlight their potential clinical application and justify further clinical investigations. Full article

In the present study, we developed a moxifloxacin (MXF)-encapsulated liposome-enriched alginate nanocomposite hydrogel coating. MXF was encapsulated in soy lecithin (SL:MXF:2:1) via the probe sonication method with an average efficiency of 80%. Two different manufacturing methods, including a micropipetting and a T-shaped microfluidic junction (TMJ) device technique, were used to incorporate the MXF-encapsulated liposomes into hydrogel matrices and layered as a coating on polymeric substrate material. Drug encapsulation and its incorporation into the hydrogel matrix significantly enhanced its stability and facilitated a prolonged drug release profile. A relatively rapid drug release was observed in the MXF-encapsulated liposome-loaded polymeric particulate layer developed via the micropipetting than the TMJ device technique. The findings confirmed sustained drug release behavior due to a hydrogel particulate structural uniformity conferred by the micromachine device, TMJ. Thus, these nanocomposite hydrogel coatings achieved can serve as a promising candidate for the treatment of ophthalmic or mucosal membrane infections. Full article

Background/Objectives: Polymeric monoaxial nanofibers are gaining prominence due to their numerous applications, particularly in functional scenarios such as wound management. The study successfully developed and built a special-purpose vessel and device for fabricating polymeric nanofibers. Fabrication of composite scaffolds from piezoelectric poly(vinylidenefluoride-trifluoroethylene) copolymer (PVDF-TrFE) nanofibers encapsulated with myrrh extract was investigated. Methods: The gyrospun nanofibers were characterized using SEM, EDX, FTIR, XRD, and TGA to assess the properties of the composite materials. The study also investigated the release profile of myrrh extract from the nanofibers, demonstrating its potential for sustained drug delivery. The composite’s antimicrobial properties were evaluated using the disc diffusion method against various pathogenic microbes, showcasing their effectiveness. Results: It was found that an 18% (w/v) PVDF-TrFE concentration produces the best fiber mats compared to 20% and 25%, resulting in an average fiber diameter of 411 nm. Myrrh extract was added in varying amounts (10%, 15%, and 20%), with the best average fiber diameter identified at 10%, measuring 436 nm. The results indicated that the composite nanofibers were uniform, bead-free, and aligned without myrrh. The study observed a cumulative release of 79.66% myrrh over 72 h. The release profile showed an initial burst release of 46.85% within the first six hours, followed by a sustained release phase. Encapsulation efficiency was 89.8%, with a drug loading efficiency of 30%. Antibacterial activity peaked at 20% myrrh extract. S. mutans was the most sensitive pathogen to myrrh extract. Conclusions: Due to the piezoelectric effect of PVDF-TrFE and the significant antibacterial activity of myrrh, the prepared biohybrid nanofibers will open new avenues toward tissue engineering and wound healing applications. Full article

Objectives: This study evaluated the design of a sustained-release contact lens (CL) device loading tranilast (TRA) and determined the usefulness of these CLs in Japanese albino rabbits. Methods: The sustainable CLs in this study were prepared by combining three CLs with different water contents and soaking methods under high-pressure and high-temperature using an autoclave method (AC-method). Results: Both the CLs prepared with the conventional soaking method (stir-method) and AC-methods were transparent in all three types of CLs. The loaded TRA contents in the CLs when using the AC-method were higher than those prepared using the stir-method for all three types of CLs. TRA contents were also higher when loaded into the cation-type lenses as compared to the other lenses. Moreover, the sustainable release of TRA from the TRA-loaded cation-type CL using the AC-method was significantly higher than those found for the other CLs. No corneal wounds were observed in any of the rabbits given the three types of TRA-loaded CLs for 7 days. Furthermore, the TRA-loaded CL sustainably released TRA into the lacrimal fluid in the rabbit. Conclusions: The TRA-loaded CL prepared using the AC-method overcame the limitations normally associated with the stir-method, such as the high burst release and low drug uptake. Full article

Glaucoma, a primary cause of irreversible blindness, is most effectively managed by reducing intraocular pressure (IOP). Topical eye drops, which are conventional treatments, frequently encounter constraints regarding patient compliance, inconsistent dosage, and tolerability. Slow-release drug delivery systems have emerged as a promising innovation in response to these challenges. The objective of these systems is to enhance the efficacy of treatment and patient compliance by ensuring the consistent and sustained delivery of therapeutic agents over extended periods. Implantable devices, injectable formulations, and external applications are all categorized as slow-release therapies. By delivering medication directly to the target tissues in a controlled manner, these technologies have the potential to circumvent common issues associated with traditional regimens, such as forgotten doses or improper administration. These systems have been shown to obtain clinically meaningful reductions in IOP in studies, with some demonstrating efficacy that is comparable to that of established daily topical treatments. Despite their potential, slow-release therapies encounter obstacles that necessitate resolution. Potential complications during implantation or removal, long-term biocompatibility, and the cost of treatment are all areas of concern. Furthermore, further investigation is required to comprehensively assess their relative economic feasibility, patient acceptability, and long-term safety profiles in comparison to conventional treatments. This review summarizes the most recent findings in the scientific literature, underlining the role and possible limits of slow-release therapies in glaucoma with the aim of offering a comprehensive understanding of their potential clinical applications and challenges. This emphasizes the potential for these innovations to revolutionize care by addressing current knowledge gaps, while also emphasizing the areas in which further development and research are required. Full article

Background: Cannabidiol (CBD) is a natural compound from the Cannabis sativa L. plant, which has anti-inflammatory, anti-nociceptive, neuroprotective, and antibacterial activities. Objective: The aim of this study was to develop a sustained-release device of CBD that can provide an antibacterial effect against the Gram-positive bacteria Streptococcus mutans and Staphylococcus aureus for extended periods of time. Methods: CBD was incorporated into the biodegradable PURASORB 5010 or PURASORB 7510 DL-lactide/glycolide polymers using either dimethylsulfoxide (DMSO) or acetone as the solvent, and the dried polymer scaffolds were exposed daily to a fresh culture of bacteria. The bacterial growth was determined daily by optical density, and the metabolic activity of biofilms was determined using the MTT assay. Biofilm formation on the polymer scaffolds was visualized by HR-SEM. Its anti-inflammatory effect was determined by measuring the IL-6 release from LPS-stimulated RAW 264.7 macrophages by ELISA. Cell cytotoxicity on normal Vero epithelial cells was determined by the MTT assay. The daily release of CBD was determined by gas chromatography–mass spectrometry (GC-MS). Results: PURASORB 5010/CBD scaffolds had antibacterial activity against S. mutans UA159, S. aureus ATCC25923, and a clinical isolate of a multidrug-resistant S. aureus (MDRSA CI-M) strain for the tested period of up to 17 days. PURASORB 7510/CBD scaffolds also had antibacterial activity, but overall, it was less effective than PURASORB 5010/CBD over time. The addition of PEG400 to the copolymers significantly increased the antibacterial activity of PURASORB 7510/CBD but not of PURASORB 5010/CBD. The daily release of CBD from the polymer scaffolds was sufficient to reduce the LPS-induced IL-6 secretion from RAW 264.7 macrophages, and importantly, it was not cytotoxic to either RAW 264.7 macrophages or Vero epithelial cells. The daily release of CBD was found to be between 1.12 and 9.43 µg/mL, which is far below the cytotoxic dose of 25 µg/mL. Conclusions: The incorporation of CBD into the biodegradable PURASORB 5010 can be used to prepare sustained-release devices for medical purposes where combined antibacterial and anti-inflammatory activities are desirable. Full article

Hydrogel microneedles (HMNs) have emerged as a transformative platform for minimally invasive drug delivery and biosensing, offering enhanced bioavailability, controlled drug release, and real-time biomarker detection. By leveraging swelling hydrogels, nanomaterial integration, and stimuli-responsive properties, HMNs provide precision medicine capabilities across diverse therapeutic and diagnostic applications. However, challenges remain in mechanical stability, as hydrogel-based MNs must balance flexibility with sufficient strength for skin penetration. Drug retention and controlled release require optimization to prevent premature diffusion and ensure sustained therapeutic effects. Additionally, biosensing accuracy is influenced by variability in interstitial fluid extraction and signal transduction. Clinical translation is hindered by regulatory hurdles, scalability concerns, and the need for extensive safety validation in human trials. This review critically examines the key materials, fabrication techniques, functional properties, and testing frameworks of HMNs while addressing these limitations. Furthermore, we explore future research directions in smart wearable MNs, AI-assisted biosensing, and hybrid drug–device platforms to optimize transdermal medicine. Overcoming these barriers will drive the clinical adoption of HMNs, paving the way for next-generation patient-centered therapeutics and diagnostics. Full article

The genitourinary syndrome of menopause (GSM) is a prevalent condition impacting a substantial number of women globally. Presently, the management of GSM typically entails the administration of estrogen via oral, dermal, or vaginal routes for a prolonged period of time. This study involves the development of a polymer-based hollow cylindrical delivery system loaded with estradiol hemihydrate (E2) for prolonged delivery to the uterine cavity (EPHCD) combined with a norethindrone acetate (NETA)-loaded polymeric matrix (NLPM), with both units placed onto an intra-uterine device to form a multi-component drug delivery system for the management of GSM (MCDDS). In developing EPHCD, a central composite design (CCD) was employed to evaluate and optimize the impact of formulation factors on EPHCD release and unit weight loss. The optimized EPHCD was further assessed for its chemical integrity, surface morphology, hydration characteristics, release behavior, ex vivo permeation and cytocompatibility. The optimized EPHCD, which featured a high drug load (10%) and low ethyl cellulose-to-polycaprolactone ratio (EC-to-PCL, 10%), demonstrated favorable attributes with a cumulative drug release and weight loss of 23.78 ± 0.84% and 2.09 ± 0.21%, respectively, over a 4-week testing period. The release kinetics were further noted to obey the Peppas–Sahlin model. Evaluation of MCDDS revealed an in vitro drug release comparable to the individual units, with permeation studies displaying an initial increase in the rate of flux for both drugs during the first 2 h, followed by a subsequent decrease. Moreover, the MCDDS components showed good cytocompatibility against NIH/3T3 cells, with cell viability of more than 70%. Upon evaluation of the MCDDS system, the results of this study highlight its potential as a viable sustained-release intrauterine platform for the treatment of GSM. Full article

Cisplatin, a frequently used chemotherapeutic for the treatment of cervical cancer, causes adverse effects that limit its use. Treatment with local therapy that limits toxicity remains a challenge. The aim of this study was to develop a local intravaginal cisplatin delivery system of polycaprolactone/polyvinylpyrrolidone sheath/core fibers by coaxial electrospinning. Physicochemical properties, degradation rate, mucoadhesion, release profile, and in vitro biosafety assays were characterized. Microscopy images confirmed the coaxial nature of the fibers and showed continuous morphology and diameters of 3–9 µm. The combination of polymers improved their mechanical properties. The contact angle < 85° indicated a hydrophilic surface, which would allow its dissolution in the vaginal environment. The release profile showed a rapid initial release followed by a slow and sustained release over eight days. The degradation test showed ~50% dissolution of the fibers on day 10. The adhesion of the fibrous device to the vaginal wall lasted for more than 15 days, which was sufficient time to allow the release of cisplatin. The biosafety tests showed great cytocompatibility and no hemolysis. The characteristics of the developed system open the possibility of its application as a localized therapy against cervical cancer, reducing adverse effects and improving the quality of life of patients. Full article

mRNA-based vaccines against the COVID-19 pandemic have propelled the use of nucleic acids for drug delivery. Conventional lipid-based carriers, such as liposomes and nanolipogels, effectively encapsulate and deliver RNA but are hindered by issues such as premature burst release and immunogenicity. To address these challenges, cell membrane-coated nanoparticles offer a promising alternative. We developed a novel nanoparticle system using chitosan methacrylate-tripolyphosphate (CMATPP), which capitalizes on interactions involving membrane proteins at biointerfaces. Ionic crosslinking between chitosan methacrylate and tripolyphosphate facilitates the formation of nanoparticles amenable to coating with red blood cell (RBC) membranes, extracellular vesicles (EVs), and cell-derived nanovesicles (CDNs). Coating CMATPP nanoparticles with RBC membranes effectively mitigated the initial burst release of encapsulated small interfering RNA (siRNA), sustaining controlled release while preserving membrane proteins. This concept was extended to EVs, where CMATPP nanoparticles and CDNs were incorporated into a microfluidic device and subjected to electroporation to create hybrid CDN-CMATPP nanoparticles. Our findings demonstrate that CMATPP nanoparticles are a robust siRNA delivery system with suppressed burst release and enhanced membrane properties conferred by cell or vesicle membranes. Furthermore, the adaptation of the CDN-CMATPP nanoparticle formation in a microfluidic device suggests its potential for personalized therapies using diverse cell sources and increased throughput via automation. This study underscores the versatility and efficacy of CMATPP nanoparticles in RNA delivery, offering a pathway towards advanced therapeutic strategies that utilize biomimetic principles and microfluidic technologies. Full article

With the continuous progress of biomedical technology, biomaterial coatings play an important role in improving the performance of medical devices and promoting tissue repair and regeneration. The application of natural medicine to biological materials has become a hot topic due to its diverse biological activity, low toxicity, and wide range of sources. This article introduces the definition and classification of natural medicines, lists some common natural medicines, such as curcumin, allicin, chitosan, tea polyphenols, etc., and lists some biological activities of some common natural medicines, such as antibacterial, antioxidant, antitumor, and other properties. According to the different characteristics of natural medicines, physical adsorption, chemical grafting, layer-by-layer self-assembly, sol–gel and other methods are combined with biomaterials, which can be used for orthopedic implants, cardiovascular and cerebrovascular stents, wound dressings, drug delivery systems, etc., to exert their biological activity. For example, improving antibacterial properties, promoting tissue regeneration, and improving biocompatibility promote the development of medical health. Although the development of biomaterials has been greatly expanded, it still faces some major challenges, such as whether the combination between the coating and the substrate is firm, whether the drug load is released sustainably, whether the dynamic balance will be disrupted, and so on; a series of problems affects the application of natural drugs in biomaterial coatings. In view of these problems, this paper summarizes some suggestions by evaluating the literature, such as optimizing the binding method and release system; carrying out more clinical application research; carrying out multidisciplinary cooperation; broadening the application of natural medicine in biomaterial coatings; and developing safer, more effective and multi-functional natural medicine coatings through continuous research and innovation, so as to contribute to the development of the biomedical field. Full article

Microfluid-derived liposomes (M-Lipo) exhibit great potential as drug and functional substance carriers in pharmaceutical and food science. However, the low liposome membrane stability, attributed to the liquid core, limits their application range. Oleosin, a natural surfactant protein, can improve the stability of the lipid nanoparticle membrane against various environmental stresses, such as heat, drying, and pH change; in addition, it can enable sustained drug release. Here, we proposed the fabrication of oleosin-coated M-Lipo (OM-Lipo) through self-assembly on a microfluidic chip and the evaluation of its anticancer drug (carmustine) delivery efficiency. Nanoparticle characterization revealed that the oleosin coating slightly lowered the membrane potential of M-Lipo and greatly improved their dispersibility. Additionally, the in vitro drug release profile showed that the oleosin coating improved the sustained release of the hydrophobic drug from the phospholipid bilayer in body temperature. Our results suggest that OM-Lipo has sufficient potential in various fields, based on its easy production, excellent stability, and biocompatibility. Full article

Microneedle (MN) technology has emerged as a promising approach for delivering therapeutic agents to the skin, offering significant potential in treating various dermal conditions. Among these technologies, hydrogel-forming microneedles (HFMNs) represent a transformative advancement in the management of dermal diseases through non-invasive drug delivery. These innovative devices consist of micrometer-sized needles made of native or crosslinked hydrophilic polymers, capable of penetrating the stratum corneum without damaging underlying tissues. Upon insertion, HFMNs rapidly absorb interstitial fluid, swelling to form a hydrogel conduit that enables the efficient transport of therapeutic agents directly into the dermal microcirculation. The non-invasive nature of HFMNs enhances patient compliance by eliminating the pain and discomfort associated with traditional hypodermic needles. This technology allows for the delivery of a wide range of drugs, including macromolecules and biomacromolecules, which are often difficult to administer dermally due to their size and polarity. Moreover, HFMNs provide controlled and regulated release profiles, enabling sustained therapeutic effects while minimizing systemic side effects. Additionally, HFMNs can be used for both drug delivery and real-time interstitial fluid monitoring, offering valuable insights into disease states and treatment responses. This dual functionality positions HFMNs as a versatile dermatology tool capable of effectively addressing various dermal complications. This review explores the potential use of polymeric biomaterials in HFMN fabrication and their application in treating major dermal disorders, such as acne, psoriasis, and other skin conditions. Furthermore, the review highlights the non-invasive nature of MN-based treatments, underscoring their potential to reduce patient discomfort and improve treatment adherence, as supported by the recent literature. Full article